Enterprise Innovation

Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

News

Preclinical Model Offers New Insights into Parkinson’s Disease Process

July 23, 2024

A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according...
Machine Learning Helps Define New Subtypes of Parkinson’s Disease

July 16, 2024

Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. 
Scientists Identify Blood Vessel Repair Cells

July 3, 2024

Endothelial cells with a distinct gene-expression signature play a key role in the development and repair of blood vessels throughout life, according to a new study by Weill...